Antitumor Activities of Interleukin-12 in Melanoma

作者：Wei Gao, Jun Pan, Jianping Pan · 发表于：Cancers · 年份：2022 · DOI：10.3390/cancers14225592 · 被引用次数：26 · 研究领域：Immunotherapy and Immune Responses、Toxin Mechanisms and Immunotoxins、CAR-T cell therapy research

Melanoma is the most common and serious malignant tumor among skin cancers. Although more and more studies have revolutionized the systematic treatment of advanced melanoma in recent years, access to innovative drugs for melanoma is still greatly restricted in many countries. IL-12 produced mainly by antigen-presenting cells regulates the immune response and affects the differentiation of T cells in the process of antigen presentation. However, the dose-limited toxicity of IL-12 limits its clinical application. The present review summarizes the basic biological functions and toxicity of IL-12 in the treatment of melanoma and discusses the clinical application of IL-12, especially the combination of IL-12 with immune checkpoint inhibitors, cytokines and other therapeutic drugs. We also summarize several promising technological approaches such as carriers that have been developed to improve the pharmacokinetics, efficacy and safety of IL-12 or IL-12 encoding plasmid application.